Viking Therapeutics Stock In Focus As Earnings Near And Obesity Trial Advances

• Viking Therapeutics has moved oral VK2735 into the SUNRISE Phase 3 obesity program and expanded a maintenance dosing study, building on prior Phase 2 data that showed up to 12.2% weight reduction with once daily treatment.
• The scale and duration of the SUNRISE and VANQUISH trials, each running for more than a year with hundreds to thousands of participants, highlight how heavily Viking is investing in VK2735 as its key obesity asset while still operating without revenue.
• This article examines how Viking Therapeutics' substantial VK2735 Phase 3 commitment and upcoming loss-making earnings report shape its investment narrative.

Scan beyond Viking Therapeutics and line up other obesity and metabolic names that could be setting up for the next move with the hand picked 33 healthcare AI stocks.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you need to believe VK2735 can move from a purely clinical asset to a real obesity franchise across injectable and oral formats. In the near term, the story is dominated by execution. The Phase 3 VANQUISH injectables and the new SUNRISE oral program now drive the key efficacy and safety readouts that could reshape the business profile from pure cash burn.

The biggest operational risk is straightforward. Viking still has no revenue while research and development spending and net losses remain heavy, so any trial delay or safety issue in SUNRISE or VANQUISH would affect that path most. The fresh SUNRISE start does not change that risk; it increases how central VK2735 outcomes are to the whole story.

The SUNRISE Phase 3 launch for oral VK2735 is the announcement that matters most in this context. Two 68 week trials, each with 560 adults and multiple dose arms, extend Viking Therapeutics’ weight loss program into long duration oral treatment in both non diabetic and type 2 diabetic obesity. Those studies now sit alongside the fully enrolled VANQUISH injectables.

For you as a shareholder, that creates a clear cluster of catalysts. VANQUISH injectables, SUNRISE oral, and the expanded maintenance dosing trial all test different use cases for the same dual GLP 1 and GIP mechanism, from initiation to long term maintenance. The flip side is concentration risk, since any weak efficacy or tolerability signal would echo across almost everything Viking is currently funding.

Viking Therapeutics Earnings Setup Behind The Trials

Viking Therapeutics' current analyst story hinges on VK2735, but the numbers behind that story are stark. The group has no revenue today and reported a loss of $359.6 million in its latest year, which keeps the focus squarely on how long cash can support the obesity and amylin programs before any product sales arrive.

Analysts who model the business out to 2029 are effectively asking investors to evaluate a full transition from clinical stage to commercial stage over the next few years. Their base case ties the VK2735 obesity push to revenue of $118.5 million and assumes profit margins eventually line up with the wider US biotech sector. For an investor following Viking Therapeutics, that forecast is less about precision and more about framing how large the shift would need to be to cover the current cash burn.

Valuation work in these reports takes that 2029 snapshot and backs into an implied P/E. To reconcile the analyst price target with earnings of $12.9 million in 2029, the stock would need to trade on a P/E multiple of 1,109.1x, which is far above the 21.6x currently quoted for the broader US biotech industry. That large gap highlights how sensitive the setup is to any change in expected margins, timing, or scale of VK2735 uptake.

Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This embeds yearly revenue growth from effectively zero and an earnings increase of about $372.5 million from current earnings of a $359.6 million loss.

Uncover why Viking Therapeutics' fair value indicates a 268% potential upside to its current price that may not last much longer.

Exploring Other Perspectives

Some of the most optimistic Viking Therapeutics analysts built their story around revenue of about US$497.5 million and earnings of roughly US$62.2 million by 2029, assuming VK2735 gains broad adoption. That is far above the US$118.5 million and US$12.9 million consensus view. With SUNRISE now underway, those narratives are likely to be revisited as you compare different scenarios for yourself.

Explore 3 other Viking Therapeutics fair value estimates, including one that suggests potential upside of as much as 276% from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• See our latest analysis for Viking Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Looking For More Investment Ideas Beyond Viking Therapeutics?

Once you have a view on Viking Therapeutics, it often helps to set it against a wider watchlist so you can compare risk, balance sheet strength, and potential return profiles across different companies.

• For investors who care most about resilience, consider starting with a 32 resilient stocks with low risk scores that can help you focus on businesses with more measured risk profiles.
• If you are hunting for value opportunities backed by fundamentals, line up candidates using a 33 high quality undervalued stocks that screens for quality alongside pricing.
• Those prioritizing financial strength can build a shortlist through a list of solid balance sheet and fundamentals (25 results) that highlights companies with sturdier finances.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com